MediPrint® Ophthalmics Announces Promising Results from Its SIGHT-2 Phase 2b Group 1 Clinical Study
Human Trial with Novel Glaucoma Treatment Rendered a Clinically Meaningful
MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset
Company Also Announces Move into New San Diego Headquarters SAN
MediPrint™ Ophthalmics Announces Initial Series A Funding Success
Plus, Company Comments on Its Poster at Prestigious American Glaucoma
MediPrint™ Ophthalmics Announces Acceptance and Presentation of Poster at the Upcoming GSLS in Las Vegas
Plus, Company Advances Plans for Phase 2b Trial in 2022
MediPrint™ Ophthalmics Announces Promising Results From Its Primary Market Research
Plus, Company Receives Patent for Novel Post-Cataract Surgery Lens SAN
MediPrint featured in Review of Optometry
The Coming Rise of Drug-delivery Contact Lenses This novel new
MediPrint™ Ophthalmics Announces New Corporate Branding and New Website
Plus, Company Spotlights its Successful First-in-human Clinical Study Results
MediPrint™ Ophthalmics Announces Successful Completion of Its SIGHT-1 Phase 2a Clinical Study
First-in-human Trial with Novel Glaucoma Treatment Confirmed Favorable Safety
Leo Lens Pharma Achieves Two Significant Milestones – FDA IND Submission and Seed Round Fundraising Success
IND Paves the Way to Phase 2a Clinical Study